Cargando…
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
BACKGROUND: Physical activity is known to have anti-cancer effects, including immunomodulatory actions. This study investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 therapy to enhance efficacy in patients with unresectable HCC. METHODS: The physica...
Autores principales: | Liu, Xue-Feng, Zhu, Xiao-Dong, Feng, Long-Hai, Li, Xiao-Long, Xu, Bin, Li, Kang-Shuai, Xiao, Nan, Lei, Ming, Sun, Hui-Chuan, Tang, Zhao-You |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978397/ https://www.ncbi.nlm.nih.gov/pubmed/35379324 http://dx.doi.org/10.1186/s40164-022-00275-0 |
Ejemplares similares
-
Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus
TACE in Unresectable Hepatocellular Carcinoma: A Retrospective
Analysis
por: Zhao, Shu, et al.
Publicado: (2022) -
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Wu, Jia-Yi, et al.
Publicado: (2021) -
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
por: Huang, Cheng, et al.
Publicado: (2021) -
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023) -
Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
por: Jia, Meng, et al.
Publicado: (2022)